UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of inc ...

DURECT Corporation (NASDAQ:DRRX) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Norman Sussman - Chief Medical Officer Conference Call Participants Rick Miller - Cantor Fitzgerald Thomas Yip - H.C. Wainwright Operator Greetings. And welcome to the DURECT Corporation Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of incorpor ...

DURECT Corp, Inc. (NASDAQ:DRRX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Matthew Hogan - IR James Brown - Co-Founder, CEO, President & Director Norman Sussman - Chief Medical Officer Conference Call Participants François Brisebois - Oppenheimer Thomas Yip - HC Wainwright Geoffrey de Sibert - KB Advisors Matthew Hogan Good afternoon, and welcome to our First Quarter 2022 Earnings Conference Call. This is Matt Hogan, from DURECT Corporation. Before beginning, I'd like to re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of incorpo ...

DURECT Corporation (NASDAQ:DRRX) Q4 2021 Earnings Conference Call March 7, 2022 4:30 PM ET Company Participants Mike Arenberg - Chief Financial Officer Matt Hogan - Former Chief Financial Officer Jim Brown - President and CEO Dr. WeiQi Lin - Executive Vice President, R&D and Principal Scientist Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Francois Brisebois - Oppenheimer Ed Arce - H.C. Wainwright Operator Greetings. And welcome to the DURECT Corporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of ...

DURECT Corporation (NASDAQ:DRRX) Q3 2021 Earnings Conference Call November 2, 2021 4:30 PM ET Company Participants Mike Arenberg - Chief Financial Officer Jim Brown - President and Chief Executive Officer Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Francois Brisebois - Oppenheimer & Company Thomas Yip - H.C. Wainwright Operator Greetings. Welcome to the DURECT Corporation Third Quarter 2021 Earnings Call. [Operator Instructions] Please note this con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of inc ...

DURECT Corporation (NASDAQ:DRRX) Q2 2021 Results Conference Call July 29, 2021 4:30 PM ET Company Participants Mike Arenberg - CFO Jim Brown - President and CEO Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Francois Brisebois - Oppenheimer Thomas Yip - H.C. Wainwright Mike Arenberg Good afternoon, and welcome to our Second Quarter 2021 Earnings Conference Call. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. I will provide a brie ...